We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Argentum Wins Invalidation of J&J Unit’s Cancer Drug Patent

Law360, Los Angeles (January 17, 2018, 11:07 PM EST) -- The U.S. Patent Trial and Appeal Board ruled Wednesday that a patent for Johnson & Johnson’s Zytiga prostate cancer drug described an obvious process, invalidating the last remaining patent blocking Argentum Pharmaceuticals LLC from making a generic version of a product that reaped $2.26 billion in sales in 2016.

Wednesday’s decision said Janssen Oncology Inc.’s U.S. Patent No. 8,822,438, which covers Zytiga’s chemical combination for fighting prostate cancer, could have been developed using prior patents. Finding for Argentum, PTAB ruled the J&J patent used a chemical...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.